Jardiance receives FDA approval to tackle kidney disease and cardiovascular risks
The U.S. Food and Drug Administration (FDA) has granted approval for Jardiance (empagliflozin) 10 mg tablets, a significant development announced jointly by Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY). This approval pertains to the use of Jardiance in reducing the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, […]